Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association
Cardiovascular disease (CVD) is the leading cause of death in the United States and is responsible for 17% of national health expenditures. As the population ages, these costs are expected to increase substantially. To prepare for future cardiovascular care needs, the American Heart Association deve...
Gespeichert in:
Veröffentlicht in: | Circulation (New York, N.Y.) N.Y.), 2011-03, Vol.123 (8), p.933-944 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 944 |
---|---|
container_issue | 8 |
container_start_page | 933 |
container_title | Circulation (New York, N.Y.) |
container_volume | 123 |
creator | HEIDENREICH, Paul A TROGDON, Justin G LLOYD-JONES, Donald M NELSON, Sue A NICHOL, Graham ORENSTEIN, Diane WILSON, Peter W. F JOSEPH WOO, Y KHAVJOU, Olga A BUTLER, Javed DRACUP, Kathleen EZEKOWITZ, Michael D ANDREW FINKELSTEIN, Eric YULING HONG CLAIBORNE JOHNSTON, S KHERA, Amit |
description | Cardiovascular disease (CVD) is the leading cause of death in the United States and is responsible for 17% of national health expenditures. As the population ages, these costs are expected to increase substantially.
To prepare for future cardiovascular care needs, the American Heart Association developed methodology to project future costs of care for hypertension, coronary heart disease, heart failure, stroke, and all other CVD from 2010 to 2030. This methodology avoided double counting of costs for patients with multiple cardiovascular conditions. By 2030, 40.5% of the US population is projected to have some form of CVD. Between 2010 and 2030, real (2008$) total direct medical costs of CVD are projected to triple, from $273 billion to $818 billion. Real indirect costs (due to lost productivity) for all CVD are estimated to increase from $172 billion in 2010 to $276 billion in 2030, an increase of 61%.
These findings indicate CVD prevalence and costs are projected to increase substantially. Effective prevention strategies are needed if we are to limit the growing burden of CVD. |
doi_str_mv | 10.1161/CIR.0b013e31820a55f5 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_860399000</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>860399000</sourcerecordid><originalsourceid>FETCH-LOGICAL-c285t-302d503c193a9483d95d7b69a0afc19427bd620e406e51ebcb2e08b8ed515dab3</originalsourceid><addsrcrecordid>eNpdkcFu1DAQhi1ERZfCGyDkC-KUMrbjbMxttWXbSpVaFXqOJvYEjJK42A5SD7w7bncBidNoRt8_I33D2BsBp0I04sP28vYUehCKlGgloNaDfsZWQsu6qrUyz9kKAEy1VlIes5cpfS9to9b6BTuWQjbSGFixX7sQyWLKfv7K8zfiuyUvkXgY-Baj8-EnJruMGPmZT4SJuJ-fuLvZZ3L8c8ZM6SPf8JswevuwH0w0Z76LYXpCNxNFb3HmF4Qx801KwXrMPsyv2NGAY6LXh3rC7nafvmwvqqvr88vt5qqystW5UiCdBmWFUWjqVjmj3bpvDAIOZVjLde8aCVRDQ1pQb3tJ0PYtOS20w16dsPf7vfcx_Fgo5W7yydI44kxhSV3bgCo6AApZ70kbQ0qRhu4--gnjQyege_TeFe_d_95L7O3hwNJP5P6G_oguwLsDUHziOEScrU__OGVk-U6rfgPe-Iz1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>860399000</pqid></control><display><type>article</type><title>Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association</title><source>Journals@Ovid Ovid Autoload</source><source>MEDLINE</source><source>American Heart Association Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>HEIDENREICH, Paul A ; TROGDON, Justin G ; LLOYD-JONES, Donald M ; NELSON, Sue A ; NICHOL, Graham ; ORENSTEIN, Diane ; WILSON, Peter W. F ; JOSEPH WOO, Y ; KHAVJOU, Olga A ; BUTLER, Javed ; DRACUP, Kathleen ; EZEKOWITZ, Michael D ; ANDREW FINKELSTEIN, Eric ; YULING HONG ; CLAIBORNE JOHNSTON, S ; KHERA, Amit</creator><creatorcontrib>HEIDENREICH, Paul A ; TROGDON, Justin G ; LLOYD-JONES, Donald M ; NELSON, Sue A ; NICHOL, Graham ; ORENSTEIN, Diane ; WILSON, Peter W. F ; JOSEPH WOO, Y ; KHAVJOU, Olga A ; BUTLER, Javed ; DRACUP, Kathleen ; EZEKOWITZ, Michael D ; ANDREW FINKELSTEIN, Eric ; YULING HONG ; CLAIBORNE JOHNSTON, S ; KHERA, Amit ; Council on Cardiovascular Nursing ; Council on Cardiopulmonary ; Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research ; Council on Epidemiology and Prevention ; Council on Arteriosclerosis ; Critical Care ; Council on Clinical Cardiology ; American Heart Association Advocacy Coordinating Committee ; Stroke Council ; Council on the Kidney in Cardiovascular Disease ; Council on Cardiovascular Radiology and Intervention ; Thrombosis and Vascular Biology ; Perioperative and Resuscitation</creatorcontrib><description>Cardiovascular disease (CVD) is the leading cause of death in the United States and is responsible for 17% of national health expenditures. As the population ages, these costs are expected to increase substantially.
To prepare for future cardiovascular care needs, the American Heart Association developed methodology to project future costs of care for hypertension, coronary heart disease, heart failure, stroke, and all other CVD from 2010 to 2030. This methodology avoided double counting of costs for patients with multiple cardiovascular conditions. By 2030, 40.5% of the US population is projected to have some form of CVD. Between 2010 and 2030, real (2008$) total direct medical costs of CVD are projected to triple, from $273 billion to $818 billion. Real indirect costs (due to lost productivity) for all CVD are estimated to increase from $172 billion in 2010 to $276 billion in 2030, an increase of 61%.
These findings indicate CVD prevalence and costs are projected to increase substantially. Effective prevention strategies are needed if we are to limit the growing burden of CVD.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/CIR.0b013e31820a55f5</identifier><identifier>PMID: 21262990</identifier><identifier>CODEN: CIRCAZ</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>American Heart Association ; Biological and medical sciences ; Blood and lymphatic vessels ; Cardiology. Vascular system ; Cardiovascular Diseases - economics ; Cardiovascular Diseases - epidemiology ; Coronary Disease - economics ; Coronary Disease - epidemiology ; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous ; Forecasting - methods ; Health Care Costs - trends ; Heart Failure - economics ; Heart Failure - epidemiology ; Humans ; Hypertension - economics ; Hypertension - epidemiology ; Medical sciences ; Neuropharmacology ; Pharmacology. Drug treatments ; Policy ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Stroke - economics ; Stroke - epidemiology ; United States - epidemiology</subject><ispartof>Circulation (New York, N.Y.), 2011-03, Vol.123 (8), p.933-944</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c285t-302d503c193a9483d95d7b69a0afc19427bd620e406e51ebcb2e08b8ed515dab3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,776,780,785,786,3674,23909,23910,25118,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23920068$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21262990$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HEIDENREICH, Paul A</creatorcontrib><creatorcontrib>TROGDON, Justin G</creatorcontrib><creatorcontrib>LLOYD-JONES, Donald M</creatorcontrib><creatorcontrib>NELSON, Sue A</creatorcontrib><creatorcontrib>NICHOL, Graham</creatorcontrib><creatorcontrib>ORENSTEIN, Diane</creatorcontrib><creatorcontrib>WILSON, Peter W. F</creatorcontrib><creatorcontrib>JOSEPH WOO, Y</creatorcontrib><creatorcontrib>KHAVJOU, Olga A</creatorcontrib><creatorcontrib>BUTLER, Javed</creatorcontrib><creatorcontrib>DRACUP, Kathleen</creatorcontrib><creatorcontrib>EZEKOWITZ, Michael D</creatorcontrib><creatorcontrib>ANDREW FINKELSTEIN, Eric</creatorcontrib><creatorcontrib>YULING HONG</creatorcontrib><creatorcontrib>CLAIBORNE JOHNSTON, S</creatorcontrib><creatorcontrib>KHERA, Amit</creatorcontrib><creatorcontrib>Council on Cardiovascular Nursing</creatorcontrib><creatorcontrib>Council on Cardiopulmonary</creatorcontrib><creatorcontrib>Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research</creatorcontrib><creatorcontrib>Council on Epidemiology and Prevention</creatorcontrib><creatorcontrib>Council on Arteriosclerosis</creatorcontrib><creatorcontrib>Critical Care</creatorcontrib><creatorcontrib>Council on Clinical Cardiology</creatorcontrib><creatorcontrib>American Heart Association Advocacy Coordinating Committee</creatorcontrib><creatorcontrib>Stroke Council</creatorcontrib><creatorcontrib>Council on the Kidney in Cardiovascular Disease</creatorcontrib><creatorcontrib>Council on Cardiovascular Radiology and Intervention</creatorcontrib><creatorcontrib>Thrombosis and Vascular Biology</creatorcontrib><creatorcontrib>Perioperative and Resuscitation</creatorcontrib><title>Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description>Cardiovascular disease (CVD) is the leading cause of death in the United States and is responsible for 17% of national health expenditures. As the population ages, these costs are expected to increase substantially.
To prepare for future cardiovascular care needs, the American Heart Association developed methodology to project future costs of care for hypertension, coronary heart disease, heart failure, stroke, and all other CVD from 2010 to 2030. This methodology avoided double counting of costs for patients with multiple cardiovascular conditions. By 2030, 40.5% of the US population is projected to have some form of CVD. Between 2010 and 2030, real (2008$) total direct medical costs of CVD are projected to triple, from $273 billion to $818 billion. Real indirect costs (due to lost productivity) for all CVD are estimated to increase from $172 billion in 2010 to $276 billion in 2030, an increase of 61%.
These findings indicate CVD prevalence and costs are projected to increase substantially. Effective prevention strategies are needed if we are to limit the growing burden of CVD.</description><subject>American Heart Association</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular Diseases - economics</subject><subject>Cardiovascular Diseases - epidemiology</subject><subject>Coronary Disease - economics</subject><subject>Coronary Disease - epidemiology</subject><subject>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</subject><subject>Forecasting - methods</subject><subject>Health Care Costs - trends</subject><subject>Heart Failure - economics</subject><subject>Heart Failure - epidemiology</subject><subject>Humans</subject><subject>Hypertension - economics</subject><subject>Hypertension - epidemiology</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Policy</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Stroke - economics</subject><subject>Stroke - epidemiology</subject><subject>United States - epidemiology</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkcFu1DAQhi1ERZfCGyDkC-KUMrbjbMxttWXbSpVaFXqOJvYEjJK42A5SD7w7bncBidNoRt8_I33D2BsBp0I04sP28vYUehCKlGgloNaDfsZWQsu6qrUyz9kKAEy1VlIes5cpfS9to9b6BTuWQjbSGFixX7sQyWLKfv7K8zfiuyUvkXgY-Baj8-EnJruMGPmZT4SJuJ-fuLvZZ3L8c8ZM6SPf8JswevuwH0w0Z76LYXpCNxNFb3HmF4Qx801KwXrMPsyv2NGAY6LXh3rC7nafvmwvqqvr88vt5qqystW5UiCdBmWFUWjqVjmj3bpvDAIOZVjLde8aCVRDQ1pQb3tJ0PYtOS20w16dsPf7vfcx_Fgo5W7yydI44kxhSV3bgCo6AApZ70kbQ0qRhu4--gnjQyege_TeFe_d_95L7O3hwNJP5P6G_oguwLsDUHziOEScrU__OGVk-U6rfgPe-Iz1</recordid><startdate>20110301</startdate><enddate>20110301</enddate><creator>HEIDENREICH, Paul A</creator><creator>TROGDON, Justin G</creator><creator>LLOYD-JONES, Donald M</creator><creator>NELSON, Sue A</creator><creator>NICHOL, Graham</creator><creator>ORENSTEIN, Diane</creator><creator>WILSON, Peter W. F</creator><creator>JOSEPH WOO, Y</creator><creator>KHAVJOU, Olga A</creator><creator>BUTLER, Javed</creator><creator>DRACUP, Kathleen</creator><creator>EZEKOWITZ, Michael D</creator><creator>ANDREW FINKELSTEIN, Eric</creator><creator>YULING HONG</creator><creator>CLAIBORNE JOHNSTON, S</creator><creator>KHERA, Amit</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110301</creationdate><title>Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association</title><author>HEIDENREICH, Paul A ; TROGDON, Justin G ; LLOYD-JONES, Donald M ; NELSON, Sue A ; NICHOL, Graham ; ORENSTEIN, Diane ; WILSON, Peter W. F ; JOSEPH WOO, Y ; KHAVJOU, Olga A ; BUTLER, Javed ; DRACUP, Kathleen ; EZEKOWITZ, Michael D ; ANDREW FINKELSTEIN, Eric ; YULING HONG ; CLAIBORNE JOHNSTON, S ; KHERA, Amit</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c285t-302d503c193a9483d95d7b69a0afc19427bd620e406e51ebcb2e08b8ed515dab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>American Heart Association</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular Diseases - economics</topic><topic>Cardiovascular Diseases - epidemiology</topic><topic>Coronary Disease - economics</topic><topic>Coronary Disease - epidemiology</topic><topic>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</topic><topic>Forecasting - methods</topic><topic>Health Care Costs - trends</topic><topic>Heart Failure - economics</topic><topic>Heart Failure - epidemiology</topic><topic>Humans</topic><topic>Hypertension - economics</topic><topic>Hypertension - epidemiology</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Policy</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Stroke - economics</topic><topic>Stroke - epidemiology</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HEIDENREICH, Paul A</creatorcontrib><creatorcontrib>TROGDON, Justin G</creatorcontrib><creatorcontrib>LLOYD-JONES, Donald M</creatorcontrib><creatorcontrib>NELSON, Sue A</creatorcontrib><creatorcontrib>NICHOL, Graham</creatorcontrib><creatorcontrib>ORENSTEIN, Diane</creatorcontrib><creatorcontrib>WILSON, Peter W. F</creatorcontrib><creatorcontrib>JOSEPH WOO, Y</creatorcontrib><creatorcontrib>KHAVJOU, Olga A</creatorcontrib><creatorcontrib>BUTLER, Javed</creatorcontrib><creatorcontrib>DRACUP, Kathleen</creatorcontrib><creatorcontrib>EZEKOWITZ, Michael D</creatorcontrib><creatorcontrib>ANDREW FINKELSTEIN, Eric</creatorcontrib><creatorcontrib>YULING HONG</creatorcontrib><creatorcontrib>CLAIBORNE JOHNSTON, S</creatorcontrib><creatorcontrib>KHERA, Amit</creatorcontrib><creatorcontrib>Council on Cardiovascular Nursing</creatorcontrib><creatorcontrib>Council on Cardiopulmonary</creatorcontrib><creatorcontrib>Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research</creatorcontrib><creatorcontrib>Council on Epidemiology and Prevention</creatorcontrib><creatorcontrib>Council on Arteriosclerosis</creatorcontrib><creatorcontrib>Critical Care</creatorcontrib><creatorcontrib>Council on Clinical Cardiology</creatorcontrib><creatorcontrib>American Heart Association Advocacy Coordinating Committee</creatorcontrib><creatorcontrib>Stroke Council</creatorcontrib><creatorcontrib>Council on the Kidney in Cardiovascular Disease</creatorcontrib><creatorcontrib>Council on Cardiovascular Radiology and Intervention</creatorcontrib><creatorcontrib>Thrombosis and Vascular Biology</creatorcontrib><creatorcontrib>Perioperative and Resuscitation</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HEIDENREICH, Paul A</au><au>TROGDON, Justin G</au><au>LLOYD-JONES, Donald M</au><au>NELSON, Sue A</au><au>NICHOL, Graham</au><au>ORENSTEIN, Diane</au><au>WILSON, Peter W. F</au><au>JOSEPH WOO, Y</au><au>KHAVJOU, Olga A</au><au>BUTLER, Javed</au><au>DRACUP, Kathleen</au><au>EZEKOWITZ, Michael D</au><au>ANDREW FINKELSTEIN, Eric</au><au>YULING HONG</au><au>CLAIBORNE JOHNSTON, S</au><au>KHERA, Amit</au><aucorp>Council on Cardiovascular Nursing</aucorp><aucorp>Council on Cardiopulmonary</aucorp><aucorp>Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research</aucorp><aucorp>Council on Epidemiology and Prevention</aucorp><aucorp>Council on Arteriosclerosis</aucorp><aucorp>Critical Care</aucorp><aucorp>Council on Clinical Cardiology</aucorp><aucorp>American Heart Association Advocacy Coordinating Committee</aucorp><aucorp>Stroke Council</aucorp><aucorp>Council on the Kidney in Cardiovascular Disease</aucorp><aucorp>Council on Cardiovascular Radiology and Intervention</aucorp><aucorp>Thrombosis and Vascular Biology</aucorp><aucorp>Perioperative and Resuscitation</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>2011-03-01</date><risdate>2011</risdate><volume>123</volume><issue>8</issue><spage>933</spage><epage>944</epage><pages>933-944</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><coden>CIRCAZ</coden><abstract>Cardiovascular disease (CVD) is the leading cause of death in the United States and is responsible for 17% of national health expenditures. As the population ages, these costs are expected to increase substantially.
To prepare for future cardiovascular care needs, the American Heart Association developed methodology to project future costs of care for hypertension, coronary heart disease, heart failure, stroke, and all other CVD from 2010 to 2030. This methodology avoided double counting of costs for patients with multiple cardiovascular conditions. By 2030, 40.5% of the US population is projected to have some form of CVD. Between 2010 and 2030, real (2008$) total direct medical costs of CVD are projected to triple, from $273 billion to $818 billion. Real indirect costs (due to lost productivity) for all CVD are estimated to increase from $172 billion in 2010 to $276 billion in 2030, an increase of 61%.
These findings indicate CVD prevalence and costs are projected to increase substantially. Effective prevention strategies are needed if we are to limit the growing burden of CVD.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>21262990</pmid><doi>10.1161/CIR.0b013e31820a55f5</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0009-7322 |
ispartof | Circulation (New York, N.Y.), 2011-03, Vol.123 (8), p.933-944 |
issn | 0009-7322 1524-4539 |
language | eng |
recordid | cdi_proquest_miscellaneous_860399000 |
source | Journals@Ovid Ovid Autoload; MEDLINE; American Heart Association Journals; EZB-FREE-00999 freely available EZB journals |
subjects | American Heart Association Biological and medical sciences Blood and lymphatic vessels Cardiology. Vascular system Cardiovascular Diseases - economics Cardiovascular Diseases - epidemiology Coronary Disease - economics Coronary Disease - epidemiology Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Forecasting - methods Health Care Costs - trends Heart Failure - economics Heart Failure - epidemiology Humans Hypertension - economics Hypertension - epidemiology Medical sciences Neuropharmacology Pharmacology. Drug treatments Policy Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopharmacology Stroke - economics Stroke - epidemiology United States - epidemiology |
title | Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T08%3A59%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Forecasting%20the%20Future%20of%20Cardiovascular%20Disease%20in%20the%20United%20States:%20A%20Policy%20Statement%20From%20the%20American%20Heart%20Association&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=HEIDENREICH,%20Paul%20A&rft.aucorp=Council%20on%20Cardiovascular%20Nursing&rft.date=2011-03-01&rft.volume=123&rft.issue=8&rft.spage=933&rft.epage=944&rft.pages=933-944&rft.issn=0009-7322&rft.eissn=1524-4539&rft.coden=CIRCAZ&rft_id=info:doi/10.1161/CIR.0b013e31820a55f5&rft_dat=%3Cproquest_cross%3E860399000%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=860399000&rft_id=info:pmid/21262990&rfr_iscdi=true |